Germany
Japan
United Kingdom
China
Antibodies
ALK mouse monoclonal antibody, clone OTI1A4
| Applications | IHC, LMNX, WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
.jpg?d=110x100 "User supplied image")
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR102D11
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR094F2
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5H8
| Applications | IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E3
| Applications | IHC |
| Reactivities | Human |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E4
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Rabbit monoclonal anti-PD-L1 Antibody, clone OR-5E4
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
Rabbit monoclonal anti-Sox2 Antibody, clone OTIR102D11
| Applications | WB |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
Special Offer: Get this product for $99/€99. Use code: "Truesample".
GFAP Capture mouse monoclonal antibody, Luminex validated, clone OTI4D11
| Applications | LMNX |
| Reactivities | Human, Mouse, Rat |
| Conjugation | Unconjugated |
| Matched ELISA Pair | TA700041 |
Anti-LGR5 mouse mAb, clone OTI2A2, DyLight 488 conjugated
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | DyLight 488 |
USD 420.00
In Stock
Mouse anti-PROM1 (CD133) monoclonal antibody
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
Anti-LGR5 mouse mAb, clone OTI2A2, bionylated
| Applications | WB |
| Reactivities | Human, Mouse |
| Conjugation | Biotin |
Mouse Monoclonal ApoE4 Antibody (4E4)
| Applications | WB |
| Reactivities | Human |
| Conjugation | Unconjugated |
USD 479.00
2 Weeks
USD 399.00
In Stock
Anti-LGR5 mouse mAb, clone OTI2A2, DyLight633 conjugated
| Applications | FC |
| Reactivities | Human, Mouse |
| Conjugation | DyLight 633 |
USD 379.00
In Stock
USD 428.00
In Stock
Active filters
Reactivities
- Human
Clonalities
- Monoclonal
Filter by
Target Symbol
- VSNL1 (271)
- ALK (269)
- KLK8 (253)
- CD4 (227)
- PDCD1 (217)
- MAP2K1 (212)
- ERBB2 (210)
- TP53 (202)
- CD5 (199)
- CDKN2A (183)
- NME1 (168)
- PGR (166)
- GFAP (163)
- ABCB1 (162)
- JUN (157)
- MKI67 (155)
- ERCC1 (153)
- MAP2K3 (150)
- GLI1 (149)
- KRT19 (139)
- UCHL1 (139)
- EGFR (135)
- TG (135)
- PECAM1 (132)
- CD274 (131)
- CTAG1B (131)
- CD68 (130)
- GADD45G (130)
- LIPG (130)
- CTNNB1 (128)
- IL6 (128)
- NBN (126)
- OTC (125)
- MSMB (123)
- HAVCR2 (121)
- VIM (121)
- CD40 (119)
- CD99 (113)
- LCN2 (112)
- PCNA (112)
- NKX3-1 (111)
- PIK3C2A (110)
- MDM2 (106)
- NUMB (106)
- ADIPOQ (105)
- CD80 (105)
- CFI (105)
- IL1RL1 (104)
- AFP (103)
- EPCAM (102)
- LGALS3 (98)
- CD47 (97)
- VWF (97)
- CD63 (96)
- CTLA4 (96)
- TOP2A (96)
- L1CAM (95)
- MAPK13 (95)
- MLANA (95)
- UBE2E3 (95)
- KRT20 (92)
- APP (91)
- IL17A (90)
- SENP2 (90)
- CD44 (89)
- TNFRSF8 (89)
- MS4A1 (88)
- CD33 (87)
- F13A1 (87)
- NKX2-1 (87)
- S100A8/A9 (87)
- BTLA (85)
- PNMT (85)
- PTPRC (85)
- TYMS (84)
- BRAF (81)
- D-DIMER (81)
- MLH1 (81)
- SAA1 (81)
- MDM4 (80)
- MIEN1 (80)
- MPO (80)
- PDCD1LG2 (76)
- CD27 (75)
- CHGA (75)
- TACC2 (75)
- LGR5 (74)
- ALDH1L1 (73)
- FGF21 (73)
- BCL2 (72)
- CD19 (71)
- NCAM1 (71)
- PROCR (71)
- TIGIT (71)
- BHLHE41 (70)
- PARVA (70)
- SPG7 (70)
- UBA52 (70)
- KIT (69)
- AKT1 (68)
Applications
Antibody Hosts
Isotypes
- IgG1 (46168)
- IgG2a (11184)
- IgG2b (10043)
- IgG (1144)
- IgG1, kappa (513)
- IgG, kappa (272)
- IgG3 (207)
- IgG2a, kappa (115)
- IgM (88)
- IgG2b, kappa (81)
- IgG1, lambda (27)
- IgG2c (21)
- Fab fragment, kappa (19)
- IgM, kappa (18)
- IgG3, kappa (15)
- IgG4 (10)
- IgG2a, lambda (3)
- IgG2 (2)
- IgG2, kappa (2)
- scFv (2)
- F(ab)2, kappa (1)
- IgA (1)
- IgG fraction (1)
- IgG1/IgK (1)
- IgG12b (1)
- IgG2, alpha (1)
- IgG2b, lambda (1)
- IgG3/IgG1 (1)
- cocktail (1)
Conjugates
Carrier-free
Knockout (KO) Validation
Modifications
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (80)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (26)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG1 format, for improved compatibility with existing reagents, assays and techniques. (20)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (19)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human Fab format, for improved compatibility with existing reagents, assays and techniques. (17)
- Phospho-specific (16)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (15)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (13)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (13)
- This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (8)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2a format, for improved compatibility with existing reagents, assays and techniques. (7)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2a format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (6)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This full-length, reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv format, for improved compatibility with existing reagents, assays and techniques. (5)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (5)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (4)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgM format, for improved compatibility with existing reagents, assays and techniques. (4)
- Modification (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgM format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original human scFv format, for improved compatibility with existing reagents, assays and techniques. (3)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG2b format, for improved compatibility with existing reagents, assays and techniques. (3)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (3)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- This full-length, reformatted human antibody was made using the variable domain sequences of the original Human scFv format, for improved compatibility with existing reagents, assays and techniques. (2)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric mouse antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This chimeric rabbit antibody was made using the variable domain sequences of the original human IgG4 format, for improved compatibility with existing reagents, assays and techniques. (1)
- NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 (primatized) format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric mouse antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric murine antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Hamster IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Human format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original Rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original murine IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG1 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This chimeric rabbit antibody was made using the variable domain sequences of the original rat IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This constant region of this antibody has been modified to bind to Protein A, allowing highly-specific purification of this antibody by Protein A-affinity column. (1)
- This full-length, chimeric mouse antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This full-length, chimeric rabbit antibody was made using the variable domain sequences of the original Chicken scFv format, for improved compatibility with existing reagents, assays and techniques. (1)
- This is a chimeric mouse antibody, based on the original rat IgG2b format, created for improved compatibility with existing reagents, assays and techniques. (1)
- This is a reformatted human IgG1 antibody based on the therapeutic Fab fragment. NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. (1)
- This reformatted antibody was made using the variable domain sequences of the original mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse IgG3 format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original Mouse scFv antibody fragment format, for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted mouse antibody was made using the variable domain sequences of the original mouse scFv format for improved compatibility with existing reagents, assays and techniques. (1)
- This reformatted rat antibody was made using the variable domain sequences of the original Rat IgG format, for improved compatibility with existing reagents, assays and techniques. (1)
Assay Types
Assay Platforms
Families
- Druggable Genome (38841)
- Transmembrane (12840)
- Transcription Factors (10725)
- Secreted Protein (6521)
- ES Cell Differentiation/IPS (5506)
- Protein Kinase (4277)
- Protease (3104)
- Stem cell - Pluripotency (2494)
- Adult stem cells (1387)
- Nuclear Hormone Receptor (919)
- Embryonic stem cells (880)
- Phosphatase (686)
- Cancer stem cells (611)
- Induced pluripotent stem cells (466)
- Stem cell relevant signaling - DSL/Notch pathway (409)
- Stem cell relevant signaling - JAK/STAT signaling pathway (328)
- P450 (308)
- Ion Channels: Other (297)
- GPCR (176)
- Stem cell relevant signaling - TGFb/BMP signaling pathway (152)
- Stem cell relevant signaling - Wnt Signaling pathway (60)
- Ion Channels: Potassium (50)
- Ion Channels: Transient receptor potential (36)
- Ion Channels: Cys-loop Receptors (28)
- Ion Channels: Sodium (9)
- Ion Channels: Calcium (4)
- Ion Channels: Glutamate Receptors (2)
- Ion Channels: Cyclic nucleotide gated (1)
Pathways
- Metabolic pathways (6254)
- Pathways in cancer (4863)
- MAPK signaling pathway (3075)
- Focal adhesion (2431)
- Prostate cancer (2330)
- Cell adhesion molecules (CAMs) (2305)
- Cytokine-cytokine receptor interaction (2254)
- T cell receptor signaling pathway (2227)
- Toll-like receptor signaling pathway (1993)
- Colorectal cancer (1933)
- Neurotrophin signaling pathway (1876)
- Hematopoietic cell lineage (1855)
- Melanoma (1839)
- Pancreatic cancer (1792)
- ErbB signaling pathway (1762)
- Bladder cancer (1746)
- Glioma (1693)
- Non-small cell lung cancer (1658)
- Endometrial cancer (1651)
- Chronic myeloid leukemia (1621)
- Regulation of actin cytoskeleton (1597)
- Cell cycle (1560)
- Progesterone-mediated oocyte maturation (1540)
- B cell receptor signaling pathway (1533)
- Jak-STAT signaling pathway (1417)
- Insulin signaling pathway (1407)
- Endocytosis (1338)
- GnRH signaling pathway (1320)
- Fc epsilon RI signaling pathway (1313)
- Apoptosis (1233)
- Renal cell carcinoma (1231)
- Acute myeloid leukemia (1187)
- Natural killer cell mediated cytotoxicity (1168)
- p53 signaling pathway (1138)
- Wnt signaling pathway (1107)
- Chemokine signaling pathway (1106)
- Leukocyte transendothelial migration (1105)
- Purine metabolism (1075)
- VEGF signaling pathway (1056)
- Small cell lung cancer (1054)
- Alzheimer's disease (1031)
- Fc gamma R-mediated phagocytosis (1013)
- Thyroid cancer (1003)
- Gap junction (965)
- Amyotrophic lateral sclerosis (ALS) (954)
- Adherens junction (946)
- Ubiquitin mediated proteolysis (927)
- Oocyte meiosis (914)
- Pyrimidine metabolism (896)
- Huntington's disease (868)
- Melanogenesis (810)
- Primary immunodeficiency (802)
- Epithelial cell signaling in Helicobacter pylori infection (784)
- Calcium signaling pathway (768)
- Adipocytokine signaling pathway (740)
- Type II diabetes mellitus (734)
- Complement and coagulation cascades (730)
- mTOR signaling pathway (721)
- NOD-like receptor signaling pathway (697)
- Long-term depression (676)
- Systemic lupus erythematosus (674)
- Parkinson's disease (671)
- Autoimmune thyroid disease (666)
- Basal cell carcinoma (666)
- Prion diseases (654)
- Long-term potentiation (646)
- Axon guidance (641)
- Glycolysis / Gluconeogenesis (627)
- Antigen processing and presentation (621)
- Tight junction (602)
- Vascular smooth muscle contraction (599)
- Arginine and proline metabolism (594)
- RIG-I-like receptor signaling pathway (581)
- Pathogenic Escherichia coli infection (576)
- Lysosome (570)
- Hypertrophic cardiomyopathy (HCM) (569)
- Viral myocarditis (540)
- Nucleotide excision repair (527)
- Graft-versus-host disease (524)
- TGF-beta signaling pathway (520)
- ECM-receptor interaction (514)
- Allograft rejection (510)
- Cytosolic DNA-sensing pathway (501)
- Dorso-ventral axis formation (494)
- Type I diabetes mellitus (478)
- Valine (478)
- leucine and isoleucine degradation (467)
- Oxidative phosphorylation (465)
- PPAR signaling pathway (463)
- Hedgehog signaling pathway (459)
- Dilated cardiomyopathy (445)
- Proteasome (434)
- Glycerolipid metabolism (415)
- Tryptophan metabolism (403)
- Lysine degradation (389)
- RNA degradation (388)
- Phosphatidylinositol signaling system (379)
- Arachidonic acid metabolism (374)
- Propanoate metabolism (362)
- Drug metabolism - cytochrome P450 (358)
- Spliceosome (353)
- One carbon pool by folate (349)
- Pyruvate metabolism (349)
- Metabolism of xenobiotics by cytochrome P450 (348)
- Fatty acid metabolism (343)
- Inositol phosphate metabolism (341)
- Histidine metabolism (331)
- Arrhythmogenic right ventricular cardiomyopathy (ARVC) (329)
- Alanine (326)
- aspartate and glutamate metabolism (326)
- Glutathione metabolism (324)
- Mismatch repair (324)
- Neuroactive ligand-receptor interaction (318)
- DNA replication (316)
- Tyrosine metabolism (309)
- Notch signaling pathway (295)
- Butanoate metabolism (282)
- Base excision repair (272)
- beta-Alanine metabolism (271)
- Glycine (259)
- serine and threonine metabolism (259)
- ABC transporters (237)
- Renin-angiotensin system (232)
- Asthma (226)
- Drug metabolism - other enzymes (226)
- Cardiac muscle contraction (222)
- Maturity onset diabetes of the young (222)
- Fructose and mannose metabolism (221)
- Vibrio cholerae infection (218)
- Retinol metabolism (209)
- Circadian rhythm - mammal (201)
- Cysteine and methionine metabolism (200)
- Homologous recombination (199)
- Amino sugar and nucleotide sugar metabolism (198)
- Starch and sucrose metabolism (196)
- Linoleic acid metabolism (171)
- Nicotinate and nicotinamide metabolism (171)
- SNARE interactions in vesicular transport (162)
- Citrate cycle (TCA cycle) (158)
- Pentose phosphate pathway (158)
- Glycerophospholipid metabolism (140)
- Terpenoid backbone biosynthesis (140)
- Regulation of autophagy (139)
- Porphyrin and chlorophyll metabolism (136)
- RNA polymerase (134)
- Sphingolipid metabolism (133)
- Aminoacyl-tRNA biosynthesis (127)
- Folate biosynthesis (126)
- Ribosome (119)
- Ascorbate and aldarate metabolism (114)
- Nitrogen metabolism (114)
- Sulfur metabolism (114)
- Other glycan degradation (113)
- Galactose metabolism (112)
- Methane metabolism (111)
- Caffeine metabolism (110)
- Fatty acid elongation in mitochondria (108)
- Primary bile acid biosynthesis (102)
- N-Glycan biosynthesis (101)
- Glyoxylate and dicarboxylate metabolism (89)
- Non-homologous end-joining (88)
- Selenoamino acid metabolism (84)
- Basal transcription factors (78)
- Cyanoamino acid metabolism (75)
- Phenylalanine metabolism (75)
- Androgen and estrogen metabolism (71)
- Synthesis and degradation of ketone bodies (71)
- Ether lipid metabolism (70)
- Thiamine metabolism (70)
- Olfactory transduction (67)
- Limonene and pinene degradation (62)
- Glycosaminoglycan degradation (55)
- Taste transduction (55)
- Pantothenate and CoA biosynthesis (40)
- C21-Steroid hormone metabolism (39)
- Biosynthesis of unsaturated fatty acids (36)
- Fatty acid biosynthesis (33)
- Glycosphingolipid biosynthesis - lacto and neolacto series (31)
- Keratan sulfate biosynthesis (30)
- Riboflavin metabolism (30)
- Vitamin B6 metabolism (30)
- alpha-Linolenic acid metabolism (30)
- Pentose and glucuronate interconversions (28)
- Glycosphingolipid biosynthesis - ganglio series (25)
- Steroid biosynthesis (21)
- Glycosphingolipid biosynthesis - globo series (20)
- leucine and isoleucine biosynthesis (16)
- D-Glutamine and D-glutamate metabolism (15)
- Taurine and hypotaurine metabolism (15)
- Phenylalanine (11)
- tyrosine and tryptophan biosynthesis (11)
- O-Glycan biosynthesis (10)
- Protein export (10)
- Biotin metabolism (5)
- Ubiquinone and other terpenoid-quinone biosynthesis (5)
- Chondroitin sulfate biosynthesis (2)
- Heparan sulfate biosynthesis (2)